A 38-year-old woman with acute promyelocytic leukemia (APL) presents to the ICU with severe bleeding from multiple sites (gums, GI tract, vagina) and petechiae. Laboratory investigations show: PT 18 sec (control 12), aPTT 45 sec (control 35), fibrinogen 85 mg/dL, D-dimer >10 µg/mL (normal <0.5), and platelet count 22,000/µL. Peripheral blood shows abnormal promyelocytes with Auer rods. What is the most appropriate immediate next step in management?

Explanation

## Clinical Context: DIC in APL This patient has **disseminated intravascular coagulation (DIC)** secondary to acute promyelocytic leukemia (APL), a medical emergency with a mortality rate >80% if untreated. ### Key Diagnostic Findings **High-Yield:** APL is the most common cause of DIC among hematologic malignancies due to release of tissue factor and cancer procoagulant from abnormal promyelocytes. | Finding | Interpretation | |---------|----------------| | PT/aPTT prolonged | Consumption of clotting factors | | Fibrinogen 85 mg/dL | Severe hypofibrinogenemia (normal >100) | | D-dimer markedly elevated | Massive fibrin formation and breakdown | | Thrombocytopenia + bleeding | Platelet consumption | | Auer rods on blood smear | Pathognomonic for APL | ### Management Algorithm ```mermaid flowchart TD A[APL with DIC + severe bleeding]:::outcome --> B{Immediate stabilization needed?}:::decision B -->|Yes| C[FFP + Cryoprecipitate transfusion]:::action C --> D[ATRA + Arsenic trioxide]:::action D --> E[Platelet/RBC transfusion PRN]:::action E --> F[Monitor coagulation, fibrinogen q6h]:::action F --> G[DIC resolution with APL remission]:::outcome B -->|No| H[Supportive care only]:::action ``` ### Why This Answer Is Correct **Key Point:** The immediate management of DIC-APL requires **simultaneous correction of coagulopathy AND initiation of definitive APL therapy**. 1. **FFP + Cryoprecipitate:** Replace consumed clotting factors and fibrinogen to stop active bleeding. Cryoprecipitate is preferred for fibrinogen repletion (10 units raises fibrinogen ~50 mg/dL). 2. **ATRA + Arsenic trioxide:** These are the definitive treatments for APL. ATRA induces differentiation of leukemic promyelocytes, reducing release of procoagulant substances and allowing DIC to resolve. Arsenic trioxide is the backbone of modern APL therapy. 3. **Timing is critical:** Delaying APL-specific therapy worsens DIC; early initiation leads to rapid resolution of coagulopathy as leukemic burden decreases. **Clinical Pearl:** ATRA is contraindicated in pregnancy (teratogenic) but is safe in this non-pregnant adult. The combination of ATRA + arsenic trioxide achieves cure rates >90% in APL. **High-Yield:** DIC in APL is **self-limited** — it resolves with successful treatment of the underlying leukemia. Do NOT use anticoagulation (heparin) as first-line; it worsens bleeding. [cite:Robbins 10e Ch 13]